奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HALO 奥洛兹美医疗

休市中 11-13 16:00:00 EST

100.27

-0.40

-0.40%

盘后99.48

-0.79-0.79%

19:56 EST

最高101.23	最低99.26	成交量227.64万
今开100.32	昨收100.67	日振幅1.95%
总市值113.80亿	流通市值113.07亿	总股本1.13亿
成交额2.28亿	换手率2.02%	流通股本1.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HALO","market":"US","secType":"STK","nameCN":"奥洛兹美医疗","latestPrice":100.27,"timestamp":1794603600000,"preClose":100.67,"halted":0,"volume":2276409,"hourTrading":{"tag":"盘后","latestPrice":99.48,"preClose":100.27,"latestTime":"19:56 EST","volume":81405,"amount":8148191.705,"timestamp":1794617788889,"change":-0.79,"changeRate":-0.007879,"amplitude":0.007978},"delay":0,"changeRate":-0.003973378364954859,"floatShares":112767633,"shares":113498000,"eps":3.970021,"marketStatus":"休市中","change":-0.4,"latestTime":"11-13 16:00:00 EST","open":100.32,"high":101.225,"low":99.26,"amount":228384466.23576,"amplitude":0.019519,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.970021,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1099285200000,"exchange":"NASDAQ","adjPreClose":100.67,"preHourTrading":{"tag":"盘前","latestPrice":100.66,"preClose":100.67,"latestTime":"09:29 EST","volume":1543,"amount":155429.25998,"timestamp":1794580199999,"change":-0.01,"changeRate":-0.000099,"amplitude":0.042421},"postHourTrading":{"tag":"盘后","latestPrice":99.48,"preClose":100.27,"latestTime":"19:56 EST","volume":81405,"amount":8148191.705,"timestamp":1794617788889,"change":-0.79,"changeRate":-0.007879,"amplitude":0.007978},"volumeRatio":0.7449950628741075,"impliedVol":0.3873,"impliedVolPercentile":0.5896},"requestUrl":"/m/hq/s/HALO","defaultTab":"news","newsList":[{"id":"1148851381","title":"异动解读｜奥洛兹美医疗盘中下跌5.23%，财报后资本结构调整影响受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1148851381","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148851381?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:39","pubTimestamp":1793975950,"startTime":"0","endTime":"0","summary":"11月6日，奥洛兹美医疗盘中下跌5.23%，报116.05美元/股，成交额3276.83万美元。消息面上，公司最新财报披露后，市场关注点除特许权使用费增长外，进一步转向资本结构调整对盈利质量与现金流的影响。市场此前一致预期其季度营收为4.91亿美元，同比增长44.40%，调整后每股收益为2.35美元，同比增长44.32%；公司已于9月完成13亿美元、2033年到期可转换优先票据私募发行，拟将净收益用于回购2027年及2028年到期的未偿可转换票据，以优化资本结构并增强财务灵活性。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"奥洛兹美医疗盘中下跌，资本结构调整引发关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185980428","title":"异动解读｜奥洛兹美医疗盘前下跌6.43%，财报后资本结构调整影响受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1185980428","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185980428?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:04","pubTimestamp":1793955878,"startTime":"0","endTime":"0","summary":"11月6日，奥洛兹美医疗盘前下跌6.43%，报115.05美元/股，成交额3.19万美元。消息面上，公司最新财报披露后，市场关注点除特许权使用费增长外，进一步转向资本结构调整对盈利质量与现金流的影响。此前市场一致预期其季度营收为4.91亿美元，同比增长44.40%，调整后每股收益为2.35美元，同比增长44.32%。公司于9月完成13亿美元、2033年到期可转换优先票据私募发行，并拟将净收益用于回购2027年及2028年到期的未偿可转换票据，以优化资本结构并增强财务灵活性。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"奥洛兹美医疗盘前下跌，资本结构调整引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136444175","title":"异动解读｜奥洛兹美医疗夜盘下跌6.96%，财报后资本结构调整影响受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1136444175","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136444175?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:04","pubTimestamp":1793927085,"startTime":"0","endTime":"0","summary":"11月6日，奥洛兹美医疗夜盘下跌6.96%，报114.4美元/股。消息面上，公司最新财报前市场一致预期其季度营收为4.91亿美元，同比增长44.40%，调整后每股收益为2.35美元，同比增长44.32%；但财报披露后，市场更关注特许权使用费增长之外，资本结构调整对盈利质量与现金流的影响。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"奥洛兹美医疗夜盘下滑，资本结构调整引发关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103433775","title":"异动解读｜奥洛兹美医疗盘后下跌5.29%，财报后市场聚焦资本结构调整影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1103433775","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103433775?lang=zh_cn&edition=full","pubTime":"2026-11-06 05:08","pubTimestamp":1793912920,"startTime":"0","endTime":"0","summary":"11月6日，奥洛兹美医疗盘后下跌5.29%，报116.46美元/股，成交额489.57万美元。消息面上，公司财报发布后，市场除关注特许权使用费驱动的增长外，也更聚焦资本结构调整对盈利质量与现金流的影响。此前市场一致预期公司本季度营收为4.91亿美元，同比增长44.40%，调整后每股收益为2.35美元，同比增长44.32%。同时，公司于9月完成13亿美元、2033年到期可转换优先票据私募发行，并拟将净收益用于回购2027年及2028年到期的未偿可转换票据，以优化资本结构并增强财务灵活性。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"奥洛兹美医疗财报后下跌，市场聚焦资本结构调整影响","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152484155","title":"异动解读｜奥洛兹美医疗盘中下跌5.22%，财报后市场聚焦资本结构调整影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1152484155","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152484155?lang=zh_cn&edition=full","pubTime":"2026-11-06 04:57","pubTimestamp":1793912229,"startTime":"0","endTime":"0","summary":"11月6日，奥洛兹美医疗盘中下跌5.22%，报123.54美元/股，成交额2.7亿美元。消息面上，公司此前披露本季度市场一致预期营收为4.91亿美元，同比增长44.40%，调整后每股收益为2.35美元，同比增长44.32%，市场关注点除特许权使用费增长外，也集中在资本结构调整对盈利质量与现金流的影响。此前公司于9月完成规模扩大的13亿美元、2033年到期可转换优先票据私募发行，并表示拟将净收益用于回购2027年及2028年到期的未偿可转换票据，以优化资本结构并增强财务灵活性。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"奥洛兹美财报后下跌，资本结构调整引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133111194","title":"财报前瞻 | 奥洛兹美医疗本季度营收预计增44.40%，机构多头占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1133111194","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133111194?lang=zh_cn&edition=full","pubTime":"2026-10-29 10:01","pubTimestamp":1793239266,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗将于2026年11月05日发布最新季度财报，市场聚焦其特许权使用费驱动的增长与资本结构调整对盈利质量与现金流的影响。市场一致预期本季度奥洛兹美医疗营收为4.91亿美元，同比增加44.40%；调整后每股收益为2.35美元，同比增加44.32%；息税前利润为2.97亿美元，同比增加37.02%；由于缺少公司针对毛利率与净利率的季度级明确指引，相关指标的具体预测暂不可得。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 奥洛兹美医疗本季度营收预计增44.40%，机构多头占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135410445","title":"异动解读｜奥洛兹美医疗盘中上涨5.23%，欧盟多市场禁售Keytruda SC裁决提振预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1135410445","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135410445?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:45","pubTimestamp":1791985517,"startTime":"0","endTime":"0","summary":"10月14日，奥洛兹美医疗盘中上涨5.23%，报115.355美元/股，成交额2745.57万美元。消息面上，公司此前宣布，海牙专门专利法院颁布禁令，认定默沙东的Keytruda SC侵犯其MDASE专利，并要求相关主体停止在比利时、法国、意大利、荷兰等多个欧洲市场制造、营销或进口该产品。该裁决同时驳回了专利无效主张，且不影响Keytruda静脉注射版本供应，显示Halozyme在药物递送专利保护上的法律地位获得强化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥洛兹美医疗上涨，欧洲禁售裁决提振预期","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162123557","title":"奥洛兹美医疗宣布：规模扩大的13亿美元可转换优先票据私募发行完成定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1162123557","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162123557?lang=zh_cn&edition=full","pubTime":"2026-09-18 11:21","pubTimestamp":1789701668,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（Halozyme Therapeutics, Inc.）今日正式对外宣布，其已成功为2033年到期的可转换优先票据私募发行完成定价。值得一提的是，此番发行的规模较此前有所扩大，总额高达13亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","HALO","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175819563","title":"奥洛兹美医疗宣布拟发行10.5亿美元可转换优先票据，2033年到期","url":"https://stock-news.laohu8.com/highlight/detail?id=1175819563","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175819563?lang=zh_cn&edition=full","pubTime":"2026-09-17 05:06","pubTimestamp":1789592812,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（Halozyme Therapeutics, Inc.）今日对外宣告，公司计划开展一项总额高达10.5亿美元的可转换优先票据发行事宜。这批票据的到期日设定为2033年，其具体条款与发行细节尚未完全披露，但此举已引发市场广泛关注。\n据悉，该公司正酝酿通过这一资本运作手段，进一步优化其财务结构并拓展资金储备。票据的转换机制、利率水平以及发行对象等核心要素，预计将在后续的正式公告中逐一揭晓。此次融资动作，被业内视为奥洛兹美医疗在当前医药行业竞争格局下的一次战略性筹谋，旨在为其研发管线与商业化进程注入新的动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125178192","title":"奥洛兹美医疗拟动用净收益回购2027年及2028年到期的未偿可转换票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1125178192","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125178192?lang=zh_cn&edition=full","pubTime":"2026-09-17 04:31","pubTimestamp":1789590671,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（Halozyme Therapeutics）日前宣布，计划将所筹集的净收益用于回购其尚未清偿的、分别于2027年与2028年到期的可转换票据。这一举措旨在优化公司资本结构，并进一步强化其财务灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","FFOX","HALO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911935","title":"板块普涨之际 十只量化评分强劲的大盘医疗保健股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911935","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911935?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:27","pubTimestamp":1786462073,"startTime":"0","endTime":"0","summary":"经历 2022-2023年板块低迷后，医疗保健板块在2026年重新积聚上涨动能。Centene Corporation以4.97分接近满分的量化评分位居榜单首位；Corcept Therapeutics、Bright Spring Health Services紧随其后，评分分别为4.93、4.91；Halozyme Therapeutics、Humana跻身前五，均获强烈“买入”评级。即便板块整体处在历史高位，个股之间量化评分分化依旧显著。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303689","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","LU0211326839.USD","LU1854103824.USD","BK4196","LU0109391861.USD","LU0345770308.USD","LU0149725797.USD","LU1153585028.USD","LU0496365809.HKD","IE00B3T34201.USD","LU0795875169.SGD","LU2279689827.SGD","LU1066053197.SGD","IE00B1BXHZ80.USD","SG9999002224.SGD","LU1066051811.HKD","LU0072461881.USD","LU1061106388.HKD","LU0390134368.USD","LU0820561818.USD","LU0130518102.USD","LU1201861165.SGD","LU2133065610.SGD","LU1074936037.SGD","SGXZ99366536.SGD","LU0889565916.HKD","LU1267930490.SGD","SGXZ81514606.USD","LU0310799852.SGD","SG9999014914.USD","LU2347655156.SGD","BK4566","LU0251132253.USD","LU2552382215.SGD","LU2065171311.SGD","LU0310800965.SGD","LU1057294990.SGD","LU0980610538.SGD","LU2357305700.SGD","LU2491049909.HKD","VEEV","IE00BJJMRY28.SGD","LU2361044949.HKD","MHIP","IE00B4JS1V06.HKD","LU0787776722.HKD","LU0170899867.USD","LU2065171402.SGD","LU0683600562.USD","LU1093756325.SGD","LU1718418525.SGD","LU2491050154.USD","LU2065169927.USD","LU0353189763.USD","LU0208291251.USD","LU0861579265.USD","FXH","RXL","LU2999663052.SGD","BK4559","LU0211327993.USD","CNCG","LU0965509283.SGD","LU1084165304.USD","LU0949170772.SGD","LU1291159041.SGD","LU1037948541.HKD","LU0114720955.EUR","LU1267930730.SGD","LU2242649171.HKD","LU0198837287.USD","LU0912757837.SGD","BK4154","LU1791710400.SGD","BK4585","GDOC","LU1037948897.HKD","BK4613","LU0158827948.USD","SG9999017495.SGD","LU2468319806.SGD","LU1093756168.USD","IE00B19Z8W00.USD","LU2552382058.USD","LU2236285917.USD","BK4504","LU0432979614.USD","LU1674673428.USD","LU0820561909.HKD","LU2211815571.USD","IE00B7KXQ091.USD","LU1023059063.AUD","IE00BFXG1179.USD","LU0154245756.USD","IE0004445015.USD","IYH","LU0187121727.USD","BK4533","IE00BJT1NW94.SGD","LU0553294199.USD","BK4588","LU0708994859.HKD","LU0965509010.AUD","VHT","LU0070302665.USD","LU1496350502.SGD","LU1934455194.USD","LU0162691827.USD","BK4007","LU1267930227.SGD","LU1670628061.USD","LU2089283258.USD","LU1983260115.SGD","LU0820562030.AUD","JDOC","LU0976567544.SGD","LU2552382132.HKD","IE00BSNM7G36.USD","IE00B19Z3581.USD","BK4198","BK4532","FHLC","LU2087625088.SGD","LU0052756011.USD","LU1934455277.USD","IE00B7SZLL34.SGD","LU0477156953.USD","LU0566484027.USD","LU2362540622.SGD","LU0122379950.USD","LU2362541273.HKD","LU0353189680.USD","IE00BZ9MQY76.HKD","LU0128525689.USD","LU1551013425.SGD","LU2361045086.USD","SG9999001176.SGD","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0077335932.USD","LU0211328371.USD","IE0005OL40V9.USD","LU1201861249.SGD","LU1069347547.HKD","LU0672654240.SGD","LU0545039389.USD","IE00BKVL7J92.USD","LU1267930573.SGD","IE0002270589.USD","LU0354030511.USD","LU1814569148.SGD","LU0320765059.SGD","LU0158827781.USD","LU1914381329.SGD","LU2362541513.USD","LU0648000940.SGD","LU0203347892.USD","LU1778281490.HKD","LU0154245673.USD","LU1989771016.USD","LU0079474960.USD","SG9999014021.USD","LU0316494557.USD","LU0689472784.USD","LU1119994496.HKD","LU0130517989.USD","LU1066051225.USD","BK4534","LU0456855351.SGD","BK4139","IE0034235188.USD","LU0234572021.USD","LU1732799900.SGD","LU0557290698.USD","NBIX","IE00B19Z3B42.SGD","LU0094547139.USD","LU1261432733.SGD","LU1066051498.USD","LU0203345920.USD","LU1035773651.USD","LU0661504455.SGD","LU0417517546.SGD","LU2089284900.SGD","LGHT","LU0965508806.USD","LU0738911758.USD","BK4581","HUM","IE000M9KFDE8.USD","LU0965509101.SGD","IE00BZ1G4Q59.USD","XLV","LU0128525929.USD","UNHW","HALO","LU0109394709.USD","SG9999014898.SGD","LU1323610961.USD","LU2271345857.HKD","IE00B1XK9C88.USD","LU1699723380.USD","LU1934455863.HKD","LU2125154935.USD","LU2361044865.SGD","LU2244417387.USD","IE00BN29S564.USD","LU1551013342.USD","SG9999013999.USD","UNHG","BTSG","LU0348723411.USD","LU2462591277.SGD","LU2264538146.SGD","LU0256863811.USD","LU2111349929.HKD","LU0097036916.USD","LU0029864427.USD","LU2028103732.USD","LU2324357040.USD","LU0107464264.USD","SG9999014906.USD","CORT","LU0823416689.USD","LU0648001328.SGD","LU2125154778.USD","BK4167","LU0354030438.USD","LU0289739699.SGD","LU0130102774.USD","PTH","UNH","LU0143551892.USD","FBT","LU0528227936.USD","LU0310800379.SGD","LU0320765489.SGD","SG9999018857.SGD","IE0004445239.USD","IE00B775H168.HKD","PSCH","SG9999014880.SGD","LU0053671581.USD","IE00BJJMRX11.SGD","SGXZ31699556.SGD","TRUH","LU1854104046.USD","LU1506573853.SGD","LU2112291526.USD","LU2461242641.AUD","SGXZ57979304.SGD","BK4528","LU0943347566.SGD","LU1720051017.SGD","LU0048584097.USD","LU1989764748.USD","LU1548497426.USD","LU2491050071.SGD","HRTS","TMED","IE00B2B36J28.USD","CNC","IE00BFSS8Q28.SGD","LU0795875086.SGD","LU1988902786.USD","LU2065170008.USD","LU2954938101.SGD","SG9999014005.SGD","LU0058720904.USD","LU1670627923.USD","IE00BWXC8680.SGD","IE00BFSS7M15.SGD","LU1559883803.SGD","LU0882574055.USD","SG9999001176.USD","SG9999002232.USD","IE00B4R5TH58.HKD","DVA","LU0345770993.USD","LU1720051108.HKD","SG9999014013.SGD","IE00BKPKM429.USD","EKG","IE00B19Z8X17.USD","LU0238689110.USD","SG9999018865.SGD","LU2023251221.USD","LU0211326755.USD","LU1989764664.SGD","IE00BFTCPJ56.SGD","LU0211331839.USD","LU0320765992.SGD","LU0708995401.HKD","IE0002141913.USD","LU1003077747.HKD","LU1791710582.SGD","IE00B19Z9Z06.USD","IE00B19Z9505.USD","FFOX","LU0342679015.USD","LU1674673691.USD","LU2089984988.USD","LU0053666078.USD","LU0130103400.USD","LU0859254822.USD","LU0477156797.USD","IHF","SGXZ51526630.SGD","LU0011850046.USD","LU1732800096.USD","SOLV","IE00BJJMRZ35.SGD","LU1983299246.USD","LU1064131342.USD","LU2357627491.SGD","IXJ","IE0009355771.USD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129297985","title":"异动解读｜奥洛兹美医疗盘中上涨16.87%，Q2业绩大超预期叠加多家投行上调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1129297985","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129297985?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:14","pubTimestamp":1786119298,"startTime":"0","endTime":"0","summary":"8月8日，奥洛兹美医疗盘中上涨16.87%，报100.23美元/股，成交额3.79亿美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。Q2调整后每股收益2.28美元，远超分析师一致预期的1.84美元，同比增长48%；营收4.81亿美元，超预期约19%，同比增长47.7%。公司同时大幅上调全年指引，预计调整后每股收益8.65至9.00美元，营收指引上调至18.35亿至19.1亿美元，均显著高于市场预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197190040","title":"Leerink Partners上调奥洛兹美医疗评级至“跑赢大盘”，目标价从83美元升至110美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197190040","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197190040?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:05","pubTimestamp":1786100712,"startTime":"0","endTime":"0","summary":"Leerink Partners将奥洛兹美医疗（Halozyme Therapeutics）的股票评级从“与大盘持平”上调至“跑赢大盘”。与此同时，这家投行还将其目标股价从83美元大幅提升至110美元，较此前预测值高出约32.5%。这一调整反映出市场对该公司未来增长前景的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","HALO","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165993122","title":"异动解读｜奥洛兹美医疗盘前上涨5.38%，Q2业绩大超预期且全年指引大幅上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1165993122","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165993122?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:32","pubTimestamp":1786091553,"startTime":"0","endTime":"0","summary":"8月7日，奥洛兹美医疗盘前上涨5.38%，报90.9美元/股，成交额2634.59美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。Q2调整后每股收益2.28美元，远超分析师一致预期的1.84美元，同比增长48%；营收4.81亿美元，超预期约19%，同比增长47.7%。公司同时大幅上调全年指引，预计调整后每股收益8.65至9.00美元，全年营收指引上调至18.35亿至19.1亿美元，均显著高于此前指引及市场预期。强劲增长主要受ENHANZE技术平台特许权使用费持续放量驱动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥洛兹美医疗盘前上涨5.38%，Q2业绩大超预期且全年指引大幅上调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125513225","title":"异动解读｜奥洛兹美医疗夜盘上涨6.08%，Q2业绩大超预期且全年指引大幅上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1125513225","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125513225?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:20","pubTimestamp":1786080031,"startTime":"0","endTime":"0","summary":"8月7日，奥洛兹美医疗夜盘上涨6.08%，报90.97美元/股，成交额2895.0美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。Q2调整后每股收益2.28美元，远超分析师一致预期的1.84美元，同比增长48%；营收4.81亿美元，超预期约19%，同比增长47.7%。公司同时大幅上调全年指引，预计调整后每股收益8.65至9.00美元，全年营收指引上调至18.35亿至19.1亿美元，均显著高于市场预期的7.94美元及17.7亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥洛兹美医疗夜盘上涨6.08%，Q2业绩大超预期且全年指引大幅上调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655806134","title":"强生（JNJ）抗头颈癌药物获FDA优先审查 拓展适应症迎来关键节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2655806134","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655806134?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:43","pubTimestamp":1785422625,"startTime":"0","endTime":"0","summary":"凭借优先审评通道，FDA审查周期将缩短至6个月，常规审批时长为10个月，有望加速这款双靶点皮下制剂落地。若头颈癌适应症顺利获批，将进一步拓宽产品收入空间，同时利好合作方Halozyme。市场持续等待FDA最终审批结论，跟踪该药物在实体瘤领域持续拓展潜力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2592432038.USD","RXL","PJP","LU1162221912.USD","LU0203347892.USD","LU0640476718.USD","BK4559","LU2129689431.USD","IE0001KFT4U8.USD","LU0466842654.USD","LU1032955483.USD","FTXH","GDOC","LU1043141123.HKD","IXJ","MEDX","IYH","IE00BDGV0183.EUR","TRUH","FFOX","LU0689472784.USD","BK4588","LU1585245621.USD","LU1280957306.USD","JNJ","LU2129689605.HKD","BMED","LU0098860793.USD","BK4550","LU0994945656.USD","HALO","LU1032466523.USD","LU0203345920.USD","LU1894683264.USD","IHE","IE0034235303.USD","IE00B1BXHZ80.USD","VHT","LABU","LU1145028129.USD","LU1261432733.SGD","LU2602419157.SGD","XLV","IE00BJJMRZ35.SGD","LU2129689514.USD","FHLC","IE00B4R5TH58.HKD","LU2403377893.USD","JDOC","LU1043141396.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168529165","title":"财报前瞻｜奥洛兹美医疗本季度营收预计增42.52%，回购计划或抬升每股收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1168529165","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168529165?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:34","pubTimestamp":1785382464,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗将于2026年08月06日美股盘后发布财报，本文梳理市场预测与关键看点。市场一致预期显示，本季度奥洛兹美医疗营收约为4.07亿美元，同比增长42.52%；调整后每股收益约为1.84美元，同比增长45.02%；息税前利润约为2.34亿美元，同比增长38.87%；目前未见对本季度毛利率与净利润或净利率的明确预测披露。上季度营收为3.77亿美元，同比增长42.23%；毛利率72.18%；归属于母公司股东的净利润为1.50亿美元，净利率39.83%；调整后每股收益为1.60美元，同比增长44.14%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜奥洛兹美医疗本季度营收预计增42.52%，回购计划或抬升每股收益","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652152322","title":"Halozyme(HALO)与Incyte(INCY)联合推进创新药INCA033989皮下注射剂型开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652152322","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652152322?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:59","pubTimestamp":1784552369,"startTime":"0","endTime":"0","summary":"双方将利用Halozyme专有的ENHANZE药物递送技术，共同推进Incyte旗下在研创新药INCA033989皮下注射剂型的开发。根据协议条款，Halozyme将从Incyte获得一笔首付款，并有资格在未来达成特定开发及商业化里程碑时获得追加付款。此外，Halozyme还将根据使用ENHANZE技术药物的未来净销售额抽取一定比例的特许权使用费。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","INCY","IDNA","IBBQ","159992","HALO","BK1574","BK4550","BK4585","BK4588","LU0053671581.USD","MEDX","BK1161","BK4139","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165004523","title":"奥洛兹美医疗与因塞特医疗达成全球合作与许可协议，利用Enhanze®技术开发皮下制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1165004523","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165004523?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:08","pubTimestamp":1784549338,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布，已与因塞特医疗签署了一项全球合作与许可协议。该协议旨在利用奥洛兹美医疗的Enhanze®技术，支持因塞特医疗旗下在研药物Inca033989开发皮下注射剂型。\n此次合作将结合双方的专业优势，探索通过皮下给药途径提升治疗便利性与患者体验的可能性。Enhanze®技术平台能够帮助大分子药物实现快速、高效的皮下递送。\n协议的达成标志着两家公司在创新药物递送解决方案领域的战略协同。此举有望为患者带来更便捷的治疗选择，并拓展相关技术的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","INCY","BK4585","LU0053671581.USD","BK4550","HALO","IDNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168121593","title":"奥洛兹美医疗与因塞特医疗达成协议，授予其Mutcalr项目Enhanze技术开发权及两项额外靶点选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1168121593","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168121593?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:04","pubTimestamp":1784549047,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布，已授予生物制药公司因塞特医疗一项关键许可。根据协议，因塞特医疗将获得使用奥洛兹美医疗专有的Enhanze药物递送技术，以开发其Mutcalr项目的权利。此项合作不仅限于单一靶点，因塞特医疗同时还获得了两项额外靶点的选择权，为未来更广泛的管线开发铺平了道路。Enhanze技术旨在通过提高皮下给药的效率和便利性，优化生物制剂的给药方式。此次授权进一步拓展了Enhanze技术的应用范围，并强化了奥洛兹美医疗在合作开发领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HALO","BK4550","BK4532","IDNA","LU0053671581.USD","INCY","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.halozyme.com","stockEarnings":[{"period":"1week","weight":-0.0324},{"period":"1month","weight":-0.1417},{"period":"3month","weight":0.0163},{"period":"6month","weight":0.4939},{"period":"1year","weight":0.4085},{"period":"ytd","weight":0.4899}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Halozyme Therapeutics, Inc.成立于1998年，于2007年11月从内华达州重新注册成立于特拉华州，是一家生物制药公司，专注于开发可改善患者护理的创新疗法并将其商业化。该公司的研究以细胞外基质为中心，围绕细胞的结构网络在组织完整性、细胞信号传导、迁移和存活中起着至关重要的作用。凭借多年研究积累的广泛专业知识，Halozyme利用其对ECM的深刻科学理解，开发针对这一复杂且生物丰富的环境的新型治疗方法和药物递送技术，旨在推进下一代治疗解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005218},{"month":2,"riseRate":0.590909,"avgChangeRate":0.022787},{"month":3,"riseRate":0.5,"avgChangeRate":0.038012},{"month":4,"riseRate":0.565217,"avgChangeRate":-0.006814},{"month":5,"riseRate":0.565217,"avgChangeRate":0.006828},{"month":6,"riseRate":0.608696,"avgChangeRate":0.049475},{"month":7,"riseRate":0.652174,"avgChangeRate":0.035849},{"month":8,"riseRate":0.521739,"avgChangeRate":0.007316},{"month":9,"riseRate":0.391304,"avgChangeRate":0.020925},{"month":10,"riseRate":0.478261,"avgChangeRate":-0.018546},{"month":11,"riseRate":0.608696,"avgChangeRate":0.052775},{"month":12,"riseRate":0.545455,"avgChangeRate":0.110354}],"exchange":"NASDAQ","name":"奥洛兹美医疗","nameEN":"Halozyme Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥洛兹美医疗,HALO,奥洛兹美医疗股票,奥洛兹美医疗股票老虎,奥洛兹美医疗股票老虎国际,奥洛兹美医疗行情,奥洛兹美医疗股票行情,奥洛兹美医疗股价,奥洛兹美医疗股市,奥洛兹美医疗股票价格,奥洛兹美医疗股票交易,奥洛兹美医疗股票购买,奥洛兹美医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}